A WEGO Health white paper examined how the change could affect patient influencers.
Talukdar will lead the firm's advisory practice, VantageRx.
The agency began working with the national reproductive center this month.
Read the February 2018 issue in its entirety.
Pharma buys back shares with tax savings; Facebook algorithm change means opportunity for patient influencers; Trump claims Azar has already lowered drug prices.
Novo Nordisk diabetes pill delivers in late-stage trial; Gilead partners with Sangamo on engineered cell therapies; Study finds antidepressants work, though with varying results.
Dohmen will continue to operate under its brand and retain its leadership team.
AbbVie reports successful elagolix trial; White House touts short-term insurance plans; Mayo Clinic chief to retire.
Gilead wins reversal of $2.5 billion payment order; Aimmune Therapeutics' peanut allergy therapy shows promise; AstraZeneca wins FDA approval on key cancer drug.
Roche to acquire Flatiron Health for $1.9B; FDA considers allowing pre-symptom Alzheimer's drug tests; Marijuana producer branches into pharma.
CMS forecasts prescription drug spending to hit $5.7T by 2026; Ipsen predicts cancer drug shopping spree; Omnicom numbers miss estimates on revenue.
The two organizations will partner on content including personal stories and expert advice.
In 2017, Interpublic reported a net income of $579 million, down 4.8% from the previous year.
IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Daniel Carucci is joining the Interpublic Group firm full-time after serving as a consultant and in roles with the U.N. Foundation and the U.S. Navy.
The company is also looking to better combine its web and social media presence.
Zimprich joins from Honeywell, where he led global business communications.
Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.